ProteKt Therapeutics is a biotechnology company pioneering the development of novel, highly selective inhibitors of Protein Kinase R (PKR) for the treatment of neurodegenerative and neuroinflammatory diseases. PKR is a key regulator of cellular stress responses, and its activation is increasingly recognized as a central contributor to the pathology of conditions such as Alzheimer's disease, ALS, and other CNS disorders.
Our lead compounds target PKR upstream of neurodegeneration, offering a mechanism-based, disease-modifying approach. Backed by strong preclinical efficacy and safety data, ProteKt’s therapeutic strategy is designed to reduce neuronal loss, dampen chronic inflammation, and improve functional outcomes.
Company Details
- Employees
- 3
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.protektx.com
- Keywords
- Tel aviv.
Protekt Therapeutics Questions
Protekt Therapeutics's website is https://www.protektx.com
Protekt Therapeutics's LinkedIn profile is https://il.linkedin.com/company/protekt-therapeutics
Protekt Therapeutics has
3 employees.
View email and phone details for 3
employees at Protekt Therapeutics.
Protekt Therapeutics's industry is
Biotechnology Research
Protekt Therapeutics's top competitors are
Betalin Therapeutics Ltd.,
X-Tosis,
Phasev,
Slate Therapeutics,
Kal-Quote,
Aigis Labs,
Pre-Cure,
Jaguahr Therapeutics,
Prilenia,
Meatgardens.
Protekt Therapeutics's categories are Biotechnology Research
